ClinicalTrials.gg
Not yet recruitingNCT07844642Updated Sep 28, 2026

Timing of Success Evaluation After Flapless Treatment of Peri-Implantitis

An observational study in Peri-implantitis, sponsored by University of Barcelona. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University of Barcelona · Observational

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Peri-Implantitis with a site in Spain — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Spain.

Planned enrollment
15th of 22
60 · median 117
Started
2026
with 5 others
Observational
22 of 50
9 open now
Primary completion
2028-09
later than 18 of 18 live
Registered
50th of 50
by date
Lead sponsor
5 of 50
University of Barcelona

Among the 50 studies in Peri-Implantitis with a site in Spain, this one is the 15th largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2026, is one of 22 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 50th registered.

Peri-Implantitis

323 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

16 of the 50 studies in Peri-Implantitis with a site in Spain are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Peri-Implantitis with a site in Spain, or all of them as a file.
02

Study summary

Peri-implantitis is an inflammatory disease around dental implants that causes progressive loss of the bone supporting the implant. Current clinical guidelines recommend treating it first with a non-surgical approach and then checking treatment success, usually between 6 and 12 weeks later. However, it is not known whether this is the best time to check the results, since no previous studies have compared different follow-up time points.

This study will follow patients with peri-implantitis who receive the same non-surgical, flapless treatment. Their implants will be checked at five different times after treatment (6 and 12 weeks, and 6, 9, and 12 months) to see how the clinical outcome changes over time. The main goal is to find out how treatment success evolves at these different time points, and whether the results seen early (at 6 weeks) match the final results seen at 12 months

03

Conditions studied

  • Peri-implantitis

Browse trials for

Keywords

  • Non-surgical treatment
  • Flapless treatment
  • Treatment success
  • Re-evaluation timing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with at least one dental implant in function for at least 12 months, diagnosed with peri-implantitis according to the 2017 World Workshop criteria, treated at the Hospital Odontològic Universitat de Barcelona.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older.
  • General health status compatible with dental treatment ().
  • Ability to understand the study, sign the form, and comply with the follow-up protocol.
  • Presence of one or more dental implants in function for at least 12 months, placed at any center, regardless of connection type or the presence of platform switching.
  • Screw-retained implant-supported prostheses (single-unit, partial, or complete).
  • Presence of at least one implant diagnosed with peri-implantitis, according to the criteria of the 2017 Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study or inability to provide .
  • Non-acceptance of the proposed treatment.
  • Pregnancy or breastfeeding.
  • Treatment with drugs or presence of diseases that may alter the healing of peri-implant tissues or interfere with the response to treatment (e.g., , systemic at immunosuppressive doses, or treatment with antiresorptive or antiangiogenic agents).
  • Implants restored with cemented prostheses.
  • Implants with mobility or with radiographic bone loss exceeding 50%.
  • Surgical or non-surgical peri-implant treatment of the affected implant within the previous 12 months.
  • Systemic antibiotic treatment within the previous 3 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Flapless treatment

    Procedure: Flapless non-surgical treatment of peri-implantitis

Interventions

  • ProcedureFlapless non-surgical treatment of peri-implantitis

    Non-surgical flapless treatment consisting of oral hygiene motivation and instructions, removal of the implant-supported prosthesis when possible, modification of the emergence profile when indicated, supra- and submucosal mechanical debridement using ultrasonic devices with periodontal tips and steel curettes, removal of granulation tissue, and curettage of the peri-implant mucosa. Followed by chlorhexidine gel twice daily for 15 days and systemic antibiotic therapy (metronidazole 500 mg three times daily for 7 days, or azithromycin 500 mg once daily for 3 days in case of allergy/contraindication)

06

What researchers measure

Primary outcomes

  1. Clinical Success Following Flapless Treatment of Peri-Implantitis

    Clinical success, recorded dichotomously (success/no success), assessed at six sites per implant. An implant is classified as a clinical success when probing depth (PD) is ≤5 mm at all six sites, bleeding on probing is present at, at most, one site and presents as an isolated spot rather than a line or profuse bleeding, and suppuration is absent at all sites.

    Time frame: 6 weeks, 12 weeks, 6 months, 9 months, and 12 months after treatment

Secondary outcomes

  1. Age (Years)

    Age at inclusion, recorded in completed years.

    Time frame: Baseline (T0)

  2. Sex (Male/Female)

    Sex of participants.

    Time frame: Baseline (T0)

  3. Smoking Status (Never Smoker/Former Smoker/Current Smoker)

    Smoking status classified as never smoker, former smoker, or current smoker. In current and former smokers, cumulative smoking exposure will be recorded in pack-years; in current smokers, daily cigarette consumption will also be recorded.

    Time frame: Baseline (T0)

  4. Periodontal Diagnosis (Stage I-IV; Grade A-C)

    Periodontal diagnosis according to the classification of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

    Time frame: Baseline (T0)

  5. Arch (Maxilla/Mandible)

    Location of the implant by dental arch.

    Time frame: Baseline (T0)

  6. Location (Anterior/Premolar/Molar)

    Implant location within the arch.

    Time frame: Baseline (T0)

  7. Implant Type (Bone Level/Tissue Level)

    Type of implant according to its design.

    Time frame: Baseline (T0)

  8. Implant Length and Diameter (mm)

    Implant length and diameter, recorded in millimeters.

    Time frame: Baseline (T0)

  9. Surface Type (Machined/Rough)

    Implant surface type.

    Time frame: Baseline (T0)

  10. Implant-Abutment Connection Type (Internal/External)

    Type of connection between implant and abutment.

    Time frame: Baseline (T0)

  11. Time in Function (Years)

    Time elapsed since implant placement, recorded in years.

    Time frame: Baseline (T0)

  12. Prosthesis Type (Single-Unit/Partial/Multiple)

    Type of implant-supported prosthesis.

    Time frame: Baseline (T0)

  13. Intermediate Abutment (Yes/No)

    Presence of an intermediate abutment.

    Time frame: Baseline (T0)

  14. Prosthetic Modification During Treatment (Yes/No)

    Whether a prosthetic modification was performed during the flapless treatment visit.

    Time frame: Flapless treatment visit (T-treatment)

  15. Modified Plaque Index (0-3)

    Presence of plaque, recorded at six sites per implant using the modified plaque index (Mombelli et al., 1987).

    Time frame: Baseline (T0), and at 6 and 12 weeks, and 6, 9, and 12 months (T1-T5)

  16. Probing Depth (mm)

    Distance, in millimeters, from the mucosal margin to the base of the peri-implant pocket, measured without the prosthesis in place, recorded at six sites per implant using a PCP-UNC 15 periodontal probe.

    Time frame: Baseline (T0), and at 6 and 12 weeks, and 6, 9, and 12 months (T1-T5)

  17. Bleeding on Probing (Present/Absent)

    Presence or absence of bleeding on probing, recorded at six sites per implant.

    Time frame: Baseline (T0), and at 6 and 12 weeks, and 6, 9, and 12 months (T1-T5)

  18. Suppuration on Probing (Present/Absent)

    Presence or absence of suppuration on probing, recorded at six sites per implant.

    Time frame: Baseline (T0), and at 6 and 12 weeks, and 6, 9, and 12 months (T1-T5)

  19. Implant-Mucosa Distance (mm)

    Distance between the mucosal margin and the implant shoulder, measured after prosthesis removal at six sites per implant. Recorded as positive when the mucosal margin is apical to the implant shoulder, and negative when coronal to it.

    Time frame: Flapless treatment visit (T-treatment)

  20. Keratinized Mucosa (mm)

    Distance between the mucosal margin and the mucogingival junction, measured at six sites per implant.

    Time frame: Flapless treatment visit (T-treatment)

  21. Retreatment Performed (Yes/No)

    Whether retreatment (re-instrumentation without adjunctive systemic antibiotics) was performed, and timing.

    Time frame: 12 weeks, and 6, 9, and 12 months (T2-T5)

  22. Need for Surgical Peri-Implant Treatment (Yes/No)

    Whether additional surgical peri-implant treatment was required, and timing.

    Time frame: 12 weeks, and 6, 9, and 12 months (T2-T5)

  23. Implant Loss (Yes/No)

    Whether the implant was lost/extracted, and timing.

    Time frame: 12 weeks, and 6, 9, and 12 months (T2-T5)

  24. Radiographic Defect Morphology (Supracrestal/Intrabony/Combined)

    Morphology of the radiographic bone defect, classified as supracrestal, intrabony, or combined, assessed on periapical radiographs obtained using the long-cone paralleling technique and analyzed with ImageJ® software after calibration using the known implant length.

    Time frame: Baseline (T0)

  25. Radiographic Bone Level (mm)

    Distance, in millimeters, between the implant shoulder and the base of the bone defect, assessed on periapical radiographs obtained using the long-cone paralleling technique and analyzed with ImageJ® software after calibration using the known implant length.

    Time frame: Baseline (T0), and at 6 and 12 months (T3, T5), or at any other visit if clinically necessary

  26. Intrabony Defect Depth (mm)

    Depth of the intrabony component of the radiographic defect, assessed on periapical radiographs.

    Time frame: Baseline (T0)

  27. Intrabony Defect Width (mm)

    Width of the intrabony component of the radiographic defect, assessed on periapical radiographs.

    Time frame: Baseline (T0)

  28. Intrabony Defect Angle (º)

    Angle of the intrabony component of the radiographic defect, assessed on periapical radiographs.

    Time frame: Baseline (T0)

  29. Treatment Trajectory (Success Without Retreatment/Success After Retreatment/Persistent Failure at 12 Months/Surgical Treatment or Implant Loss)

    Implant status at the 12-month outcome, classified as: success without retreatment; success after retreatment; persistent failure at 12 months; or surgical treatment/implant loss. An implant is considered a treatment failure if classified as either persistent failure at 12 months or surgical treatment/implant loss.

    Time frame: 12 months (T5)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.

Of 33 non-industry observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's planned 23 months is above that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 8 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Oct 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844642
Responsible party
Octavi Camps-Font (Associate Professor, University of Barcelona) — Principal investigator
First posted
Sep 28, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion